Nonalcoholic Fatty Liver Disease, Cardiovascular Risk, and Carotid Inflammation

Association Between Nonalcoholic Fatty Liver Disease and Carotid Artery Inflammation Evaluated by 18F-Fluorodeoxyglucose Positron Emission Tomography

(2014) Seung Hwan Moon et al.   ANGIOLOGY

Adiponectin predicts MMP-2 activity independently of obesity

(2014) Verónica Miksztowicz et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Increased Hs-CRP/adiponectin ratio is associated with increase carotid intima-media thickness

(2014) Huocheng Liao et al.   Lipids in Health and Disease

Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima–media thickness

(2013) Changhong Tan et al.   ATHEROSCLEROSIS

Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels

(2013) Matti J. Tikkanen et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Role of HDL in neutralizing the VLDL effect on endothelial dysfunction

(2013) Valeria Zago et al.   MICROVASCULAR RESEARCH

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches

(2013) Dragana Nikolic et al.   Nutrients

Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography

(2012) Diego Lucero et al.   CLINICAL BIOCHEMISTRY

Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance

(2012) V. Miksztowicz et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Attenuation of Rate of Change in Carotid Intima-Media Thickness by Lipid-Modifying Drugs

(2011) Sanne A.E. Peters et al.   American Journal of Cardiovascular Drugs

Metalloproteinases in metabolic syndrome

(2011) Gabriela Berg et al.   CLINICA CHIMICA ACTA

Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)]

(2011) Manfredi Rizzo et al.   CURRENT PHARMACEUTICAL DESIGN

“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses

(2011) Dimitri P. Mikhailidis et al.   Current Vascular Pharmacology

Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome

(2010) Diego Lucero et al.   CLINICA CHIMICA ACTA

Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?

(2010) Diego Lucero et al.   CLINICA CHIMICA ACTA

Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study

(2010) Egle Corrado et al.   CORONARY ARTERY DISEASE

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

(2010) Vasilios G Athyros et al.   LANCET

Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review

(2008) Silvia Sookoian et al.   JOURNAL OF HEPATOLOGY

Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease

(2007) Manfredi Rizzo et al.   ATHEROSCLEROSIS